Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells

Cisplatin (CisPt) is frequently used in the therapy of urothelial carcinoma (UC). Its therapeutic efficacy is limited by inherent or acquired drug resistance. Here, we comparatively investigated the CisPt-induced response of two different parental urothelial carcinoma cell lines (RT-112, J-82) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Höhn, Annika, Krüger, Katharina, Skowron, Margaretha A., Bormann, Stefanie, Schumacher, Lena, Schulz, Wolfgang A., Hoffmann, Michèle J., Niegisch, Günter, Fritz, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173062/
https://www.ncbi.nlm.nih.gov/pubmed/27191498
http://dx.doi.org/10.18632/oncotarget.9321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173062/
https://www.ncbi.nlm.nih.gov/pubmed/27191498
http://dx.doi.org/10.18632/oncotarget.9321

Ejemplares similares